RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
AIM ImmunoTech Stock

AIM ImmunoTech EBIT 2024

AIM ImmunoTech EBIT

-24.77 M USD

Ticker

AIM

ISIN

US00901B1052

WKN

A2PREX

In 2024, AIM ImmunoTech's EBIT was -24.77 M USD, a -22.38% increase from the -31.92 M USD EBIT recorded in the previous year.

The AIM ImmunoTech EBIT history

YEAREBIT (undefined USD)
2029e156.89
2028e-12
2027e-42.53
2026e-34.46
2025e-27.2
2024e-24.77
2023-31.92
2022-19.92
2021-17.06
2020-15.02
2019-12.44
2018-11.5
2017-11.42
2016-13.8
2015-16.65
2014-19.1
2013-17.17
2012-20.34
2011-14.3
2010-16.39
2009-13.26
2008-12.81
2007-19.29
2006-18.69
2005-9.92
2004-10.89

AIM ImmunoTech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into AIM ImmunoTech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AIM ImmunoTech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AIM ImmunoTech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AIM ImmunoTech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AIM ImmunoTech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AIM ImmunoTech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AIM ImmunoTech’s growth potential.

AIM ImmunoTech Revenue, EBIT and net profit per share

DateAIM ImmunoTech RevenueAIM ImmunoTech EBITAIM ImmunoTech Net Income
2029e118.27 M undefined156.89 M undefined34.05 M undefined
2028e51.55 M undefined-12 M undefined-10.39 M undefined
2027e9.85 M undefined-42.53 M undefined-36.36 M undefined
2026e3.86 M undefined-34.46 M undefined-28.86 M undefined
2025e1.8 M undefined-27.2 M undefined-26.16 M undefined
2024e134,663.3 undefined-24.77 M undefined-24.05 M undefined
2023202,000 undefined-31.92 M undefined-28.96 M undefined
2022141,000 undefined-19.92 M undefined-19.45 M undefined
2021135,000 undefined-17.06 M undefined-19.13 M undefined
2020163,000 undefined-15.02 M undefined-14.4 M undefined
2019140,000 undefined-12.44 M undefined-9.4 M undefined
2018367,000 undefined-11.5 M undefined-9.81 M undefined
2017437,000 undefined-11.42 M undefined-8.26 M undefined
201692,000 undefined-13.8 M undefined-7.5 M undefined
2015133,000 undefined-16.65 M undefined-15.23 M undefined
2014197,000 undefined-19.1 M undefined-17.45 M undefined
2013150,000 undefined-17.17 M undefined-16.23 M undefined
2012210,000 undefined-20.34 M undefined-17.35 M undefined
2011160,000 undefined-14.3 M undefined-9.02 M undefined
2010140,000 undefined-16.39 M undefined-13.14 M undefined
2009110,000 undefined-13.26 M undefined-7.18 M undefined
2008270,000 undefined-12.81 M undefined-12.22 M undefined
20071.06 M undefined-19.29 M undefined-18.14 M undefined
2006930,000 undefined-18.69 M undefined-19.4 M undefined
20051.08 M undefined-9.92 M undefined-12.45 M undefined
20041.23 M undefined-10.89 M undefined-24.14 M undefined

AIM ImmunoTech stock margins

The AIM ImmunoTech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AIM ImmunoTech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AIM ImmunoTech.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AIM ImmunoTech's sales revenue. A higher gross margin percentage indicates that the AIM ImmunoTech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AIM ImmunoTech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AIM ImmunoTech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AIM ImmunoTech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AIM ImmunoTech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AIM ImmunoTech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AIM ImmunoTech Margin History

AIM ImmunoTech Gross marginAIM ImmunoTech Profit marginAIM ImmunoTech EBIT marginAIM ImmunoTech Profit margin
2029e79.21 %132.65 %28.79 %
2028e79.21 %-23.28 %-20.15 %
2027e79.21 %-431.88 %-369.19 %
2026e79.21 %-893.32 %-747.94 %
2025e79.21 %-1,513 %-1,455.08 %
2024e79.21 %-18,396.09 %-17,856.84 %
202379.21 %-15,800 %-14,337.62 %
2022100 %-14,129.79 %-13,790.78 %
2021-529.63 %-12,636.3 %-14,168.15 %
2020-394.48 %-9,212.88 %-8,834.36 %
2019-537.86 %-8,887.86 %-6,717.14 %
2018-140.87 %-3,132.43 %-2,673.84 %
2017-170.71 %-2,612.36 %-1,889.93 %
2016-1,104.35 %-15,004.35 %-8,154.35 %
2015-1,101.5 %-12,518.8 %-11,451.13 %
2014-535.03 %-9,694.92 %-8,857.87 %
2013-720 %-11,446.67 %-10,820 %
2012-847.62 %-9,685.72 %-8,261.91 %
2011-550 %-8,937.5 %-5,637.5 %
2010-864.29 %-11,707.14 %-9,385.72 %
2009-427.27 %-12,054.55 %-6,527.27 %
2008-196.3 %-4,744.44 %-4,525.93 %
200712.26 %-1,819.81 %-1,711.32 %
2006-36.56 %-2,009.68 %-2,086.02 %
200563.89 %-918.52 %-1,152.78 %
2004-71.54 %-885.37 %-1,962.6 %

AIM ImmunoTech Aktienanalyse

What does AIM ImmunoTech do?

AIM ImmunoTech Inc is a US-based biotechnology company that focuses on the development of immunotherapeutics and diagnostics for humans and animals. The company has been in operation for over 30 years and specializes in the treatment of viral and autoimmune diseases. AIM ImmunoTech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing AIM ImmunoTech's EBIT

AIM ImmunoTech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of AIM ImmunoTech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

AIM ImmunoTech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in AIM ImmunoTech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about AIM ImmunoTech stock

How much did AIM ImmunoTech achieve in EBIT for the current year?

In the current year, AIM ImmunoTech has achieved an EBIT of -24.77 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company AIM ImmunoTech.

How has the EBIT of AIM ImmunoTech developed in recent years?

The EBIT of AIM ImmunoTech has increased by -22.381% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company AIM ImmunoTech?

The EBIT of AIM ImmunoTech is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does AIM ImmunoTech pay?

Over the past 12 months, AIM ImmunoTech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AIM ImmunoTech is expected to pay a dividend of 0 USD.

What is the dividend yield of AIM ImmunoTech?

The current dividend yield of AIM ImmunoTech is .

When does AIM ImmunoTech pay dividends?

AIM ImmunoTech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AIM ImmunoTech?

AIM ImmunoTech paid dividends every year for the past 0 years.

What is the dividend of AIM ImmunoTech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AIM ImmunoTech located?

AIM ImmunoTech is assigned to the 'Health' sector.

Wann musste ich die Aktien von AIM ImmunoTech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AIM ImmunoTech from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did AIM ImmunoTech pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of AIM ImmunoTech in the year 2023?

In the year 2023, AIM ImmunoTech distributed 0 USD as dividends.

In which currency does AIM ImmunoTech pay out the dividend?

The dividends of AIM ImmunoTech are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von AIM ImmunoTech

Our stock analysis for AIM ImmunoTech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AIM ImmunoTech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.